X antigen family member 3Genealiases: CT12.3a · CT12.3b · GAGED4 · PLAC6 · XAGE-3 · pp9012
Q-omics provides the consensus-scored XAGE3 profile across patient tissues and cancer cell-line models. XAGE3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, XAGE3 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, XAGE3 RNA expression shows 6,039 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, KICH, and ESCA as cancer lineages where XAGE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XAGE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XAGE3 survival associations across molecular data types. XAGE3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XAGE3 RNA expression–survival associations across cancer types. High XAGE3 expression shows unfavorable associations in HNSC, CHOL, COAD and UCEC, but favorable associations in LGG and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for XAGE3 RNA expression.
This table summarizes XAGE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for XAGE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XAGE3 shows lower tumor expression in KICH, LUAD, KIRC, BRCA, LIHC and CHOL. The KICH box plot shows higher XAGE3 RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with XAGE3 in patient tissues and cancer cell lines. In patient samples, XAGE3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, XAGE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
